Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Earnings for Precipio, Inc. (PRPO)
Earnings in 2023 (TTM): $-5,853,000
According to Precipio, Inc.'s latest financial reports the company's current earnings (TTM) are $-5,853,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Precipio, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-5,853,000 | $-5,853,000 |
| 2022 | $-12,178,000 | $-12,203,000 |
| 2021 | $-8,517,000 | $-8,550,000 |
| 2020 | $-10,598,000 | $-12,230,000 |
| 2019 | $-13,313,000 | $-13,243,000 |
| 2018 | $-15,973,000 | $-15,694,000 |
| 2017 | $-20,694,000 | $-20,694,000 |
| 2016 | $-8,269,000 | $-7,616,000 |
| 2015 | $-10,138,000 | $-32,954,000 |
| 2014 | $-13,418,000 | $-13,942,000 |
| 2013 | $-16,041,000 | $-15,987,000 |
| 2012 | $-8,181,000 | $-8,327,000 |
| 2011 | $-9,737,000 | $-9,782,000 |
| 2010 | $-2,984,000 | $-3,134,000 |
| 2009 | $-1,878,000 | $-1,920,000 |
| 2008 | $-282,000 | $-495,000 |
| 2007 | $-1,931,000 | $-2,107,000 |
| 2006 | $-2,933,000 | $-3,431,000 |
| 2005 | $-4,958,000 | $-14,993,000 |
| 2004 | $-34,466,000 | $-34,372,000 |
| 2003 | $-22,893,000 | $-22,958,000 |
| 2002 | $-21,260,000 | $-21,365,000 |
| 2001 | $-7,377,000 | $-7,401,000 |
| 2000 | $-8,481,000 | $-8,661,000 |
| 1999 | $-8,081,613 | $-9,826,886 |